Eisai Keytruda News Today : Breaking News, Live Updates & Top Stories | Vimarsana

New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer Data presented at the virtual American Society of Clinical Oncology’s Genitourinary Cancers Symposium New data for Merck & Co (MSD) and Eisai’s Keytruda plus Lenvima combination treatment has demonstrated further promise for the therapy in advanced renal cell carcinoma (RCC) – the most common form of kidney cancer in adults. The new investigational data, revealed at the virtual American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU), comes from the phase 3 KEYNO...

Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer Combination treatment topped Pfizer's Sutent in phase 3 Merck & Co/MSD and Eisai’s Keytruda plus Lenvima combination has scored positive top-line results from a phase 3 trial in advanced renal cell carcinoma (a form of kidney cancer). The results, from the KEYNOTE-581/CLEAR trial, demonstrated that Keytruda (pembrolizumab) and Lenvima (lenvatinib) met the primary endpoint of improved progression-free survival (PFS) compared to Pfizer’s Sutent (sunitinib) in first-line advanced renal cell carcinoma (RCC) patients. ...